RxDoctor Payments Data

Eric Dupree, MD

Family Medicine · Olla, LANPI 1508805532

Payments from drug & device makers

$620in general payments, 2019–2025

Across 50 payments — averaging $12.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$136
  • Sumitomo Pharma America, Inc.$85
  • Astellas Pharma US Inc$77
  • Pfizer$60
  • AbbVie$54
  • AstraZeneca$40
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$60097%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$620 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$50,470
Medicare patients
313
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$123,338
MounjaroTirzepatide91$92,689
JardianceEmpagliflozin123$87,764
OzempicSemaglutide75$78,445
FarxigaDapagliflozin Propanediol67$61,588
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$45,885
GemtesaVibegron69$28,967
MyrbetriqMirabegron82$27,194
XareltoRivaroxaban56$26,353
Tresiba Flextouch U-200Insulin Degludec28$25,875
JanuviaSitagliptin Phosphate42$25,126
TrulicityDulaglutide26$23,456
Nurtec OdtRimegepant Sulfate16$17,654
TrintellixVortioxetine Hydrobromide27$17,107
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$16,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$60$140,992205 claims
Lilly USA, LLCMounjaro, Trulicity$38$116,145117 claims
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus$15$102,22497 claims
AstraZenecaFarxiga, Breztri Aerosphere$40$77,66788 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$17$76,769128 claims
Sumitomo Pharma America, Inc.Gemtesa$85$28,96769 claims
Astellas Pharma US IncMyrbetriq$77$27,19482 claims
AbbVieLinzess$54$13,30925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Olla

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →